Overview

Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.

Phase:

Phase 3

Details

Lead Sponsor:

Azienda Ospedaliero-Universitaria Careggi

Collaborator:

University of Florence

Treatments:

Bisoprolol
Ramipril
Trastuzumab